A Radical Shift in Bionic Evolution
For decades, the concept of a truly lifelike bionic limb existed almost exclusively within the realm of science fiction. In the real world, individuals who endure traumatic amputations face an entirely different and frustrating reality. When a patient puts on a modern, high-tech robotic prosthetic, they quickly discover that the cutting-edge hardware is bottlenecked by archaic control systems. To make a mechanical hand close, an amputee often has to flex an unrelated back muscle, toggle a setting on a smartphone app, or consciously contract remaining muscle tissue in a slow, exhausting sequence. The connection is clumsy, mechanical, and deeply frustrating.
While the engineering behind robotic limbs has advanced exponentially, the technology linking those limbs to human intent has lagged far behind. This profound disconnect between human thought and machine execution is the problem that Dr. Connor Glass, Founder and CEO of Phantom Neuro, set out to solve. Instead of accepting the status quo or following the tech industry’s trend of drilling into the human skull to decode brainwaves, Glass envisioned a radically elegant middle ground. His work stands at the intersection of medicine, artificial intelligence, and robotics, aiming to make human-machine interfacing as natural, seamless, and intuitive as moving a biological arm.
The Missing Link in Modern Prosthetics
To understand the scope of the challenge Phantom Neuro is tackling, one must look at the historical and current state of prosthetics. For a significant portion of the population with upper or lower limb differences, the available options fail to restore true autonomy. Traditional external prostheses rely heavily on body-powered cables or surface electromyography (sEMG) sensors placed directly on top of the skin.
Skin-surface sensors face severe physical limitations. They are highly sensitive to sweat, shifting alignment, and temperature changes. If a user perspires or moves their residual limb inside a prosthetic socket, the electrical connection shifts, causing the robotic limb to lag, misinterpret a command, or stop working entirely. The cognitive burden placed on the user is immense; they must constantly and deliberately think about how to trigger a signal rather than simply executing a movement. Because of this high failure rate and intense mental fatigue, prosthetic abandonment rates remain shockingly high. Many amputees ultimately choose to navigate the world without their advanced robotic devices because the technology is too cumbersome to integrate into daily life.
On the opposite end of the technological spectrum lies the neurotech gold rush of Brain-Computer Interfaces (BCIs). While companies grabbing headlines focus on implanting dense electrode arrays directly into the brain’s cerebral cortex, this approach introduces steep medical hurdles. Brain surgery requires drilling into the skull, carries significant risks of infection or tissue rejection, and involves lengthy, complex clinical pathways. For the vast majority of individuals who have lost a limb, undergoing elective neurosurgery just to operate a prosthetic hand is a dangerous and impractical trade-off. The industry was left with a massive polarization: unreliable surface sensors on one side, and highly invasive brain surgery on the other.
From Medical Doctor to Neurotech Innovator
Dr. Connor Glass did not start his career with the intention of becoming a Silicon Valley-style startup executive. He began his journey in medicine, earning his medical degree from the University of Oklahoma College of Medicine. Driven by a deep desire to help patients overcome severe physical trauma, he went on to pursue a highly competitive research fellowship in Plastic Surgery at the Johns Hopkins University School of Medicine.
At Johns Hopkins, Glass specialized in advanced neuromuscular microsurgery and studied how the peripheral nervous system could be surgically reconfigured to improve prosthesis control. It was during this intense clinical immersion that he witnessed firsthand the limitations of current medical research. While working alongside brilliant academic minds and observing early BCI experiments, he saw that the solutions being developed in isolated research labs were incredibly difficult to scale for the real world.
He recognized that helping one patient at a time through hours of bespoke surgery was noble, but it would never solve the systemic issue facing millions of amputees globally. Glass realized that to create a widespread, accessible impact, he needed to bridge the gap between pure academic science and commercial product development. Consequently, he chose to pass on a traditional clinical residency program to establish Phantom Neuro, taking on the mantle of entrepreneur to build a scalable platform technology.
The Ignition of Personal and Professional Purpose
The motivation driving Glass is deeply rooted in an understanding of human vulnerability and the profound psychological weight of losing bodily autonomy. As a surgical fellow, his clinical obsession centered on the peripheral nervous system. He watched patients who had survived terrible accidents face a secondary trauma: the realization that their cutting-edge prosthetics felt like foreign tools rather than parts of their bodies.
Glass became convinced that the human body already possessed the perfect infrastructure for controlling machines; it just needed a reliable translator. When a person loses a hand, the brain still sends the exact motor signals down the arm, and the remaining muscles in the residual limb still fire in specific, predictable patterns. The signal is entirely present; it simply lacks a clear pathway to cross the barrier from organic tissue to carbon fiber and steel. This insight became his driving passion: to restore dignity, autonomy, and natural movement by unlocking the rich, untapped data streams sitting just beneath the human skin.
Engineering the Phantom X System
Founded in 2020 and headquartered in Austin, Texas, Phantom Neuro set out to build a low-risk, muscle-machine interface. The company’s core technology platform, known as Phantom X, completely bypasses the brain-surgery route by focusing entirely on the peripheral nervous system and muscle tissue.
The brilliance of the Phantom X system lies in its clinical simplicity and sophisticated backend software. Instead of drilling into bone, the approach utilizes a minor, 15-minute outpatient procedure to place small, bio-compatible sensor arrays just under the skin near the amputation site. This low-risk procedure can easily be performed by thousands of trained orthopedic and plastic surgeons worldwide, making it instantly scalable. Once implanted, these internal sensors sit directly against the muscle tissue, completely shielded from external variables like sweat, ambient temperature, or clothing friction.
These sensors capture high-fidelity electrical signals from the firing muscles and wirelessly transmit that raw data to an external control unit. This is where Phantom Neuro’s advanced machine learning algorithms take over. Rather than requiring the patient to learn a new way of thinking, the software is trained to decode the user’s natural muscle intentions. If the patient thinks about pointing an index finger, the AI immediately recognizes the unique muscular signature of that specific thought and translates it into real-time, fluid movement of the robotic hand. The technology is entirely brand-agnostic, designed as a platform that can seamlessly plug into and control any advanced robotic prosthetic or exoskeleton on the market.
Validating the Tech and Navigating the Market
Building a hardware-enabled healthcare company requires surviving a gauntlet of scientific validation, regulatory hurdles, and immense capital demands. Under Glass’s leadership, Phantom Neuro has systematically knocked down these barriers, transforming an academic concept into an industry-disrupting reality.
A major milestone for the technology came through rigorous testing, assessing the underlying platform architecture. The system successfully demonstrated high-accuracy, real-time gesture control across essential hand movements, eliminating the frustrating lag associated with traditional prosthetics and providing users with an immediate, life-like response.
This technological momentum caught the attention of both the regulatory and investment communities. The U.S. Food and Drug Administration (FDA) granted the Phantom X technology its Breakthrough Device Designation alongside the TAP (Total Product Life Cycle Advisory Program) Designation. These honors are reserved for technologies that show immense promise in treating irreversibly debilitating conditions, providing Phantom Neuro with an expedited pathway through regulatory approvals.
Following this, Phantom Neuro closed an oversubscribed $19 million Series A funding round, bringing its total capital raised to over $28 million. Crucially, the round was led by Ottobock, a global MedTech champion and leader in the fields of prosthetics, orthotics, and exoskeletons. The partnership was a massive validation of Glass’s vision. With Ottobock joining the board of directors, Phantom Neuro gained immediate access to global supply chains, commercial distribution networks, and unparalleled regulatory expertise to accelerate its path to the commercial market.
A Pragmatic View of the Neurotech Landscape
Dr. Connor Glass has quickly established himself as a prominent, grounded voice in the rapidly growing neurotechnology sector. As a speaker at major global conferences, he frequently challenges the hyper-inflated narratives surrounding the brain-computer interface market.
Glass often points out that while the valuations of brain-implant companies dominate tech headlines, the practical math and clinical realities often do not add up for widespread consumer adoption. From his perspective as a physician, the medical community must prioritize patient safety, risk reduction, and actual utility over flashy sci-fi concepts. He advocates for a “peripheral-first” philosophy.
Glass argues that because the human peripheral nervous system is highly accessible and already highly mapped, tapping into the body’s existing neuromuscular pathways is the fastest, safest, and most effective way to solve mobility issues today. By focusing on muscle-machine interfaces rather than brain surgery, Phantom Neuro bypasses decades of ethical, surgical, and psychological roadblocks, positioning itself to deliver functional solutions to patients years ahead of its direct cortical competitors.
Fostering Collaborative, High-Impact Innovation
As an executive, Glass operates with a leadership style that blends surgical precision with an open, highly collaborative entrepreneurial mindset. He credits his time at Johns Hopkins for shaping this perspective, remembering how top-tier researchers across drastically different fields willingly broke down institutional silos to work together.
At Phantom Neuro’s headquarters, Glass has deliberately cultivated a diverse team that mirrors this multidisciplinary approach. He has brought together an elite group of professionals spanning surgical medicine, mechanical engineering, advanced machine learning, and medical device regulatory affairs. His advisory network has drawn prominent experts from academia, defense research, and commercial engineering sectors, featuring experts from CTRL-Labs, DARPA, Johns Hopkins University, and Precision Neuro.
Glass’s philosophy centers around the idea of being the “master of your own destiny.” He encourages his team to pursue bold, paradigm-shifting ideas without fear of initial rejection or failure. He believes that navigating intellectual property logistics and raising venture capital requires intense focus, and he encourages structuring core concepts broadly to maximize their future utility. Glass balances this drive with deep humility, maintaining an environment where scientific data drives decisions and patient outcomes are the ultimate measure of success.
Horizons Beyond Restorative Health
While Phantom Neuro’s primary and immediate mission is to restore fluid movement, independence, and dignity to individuals with limb differences, Glass’s long-term vision extends far beyond traditional healthcare. The Phantom platform is fundamentally a human-machine interface, and its underlying technology has profound implications for the future of human capability.
The company has successfully advanced its regulatory and clinical pathway, securing official approval to conduct its first-in-human Early Feasibility Study (EFS), named the CYBORG study, in Australia. This marks a critical milestone as the company maps out its global clinical trials. Because the system decodes human intent from muscle tissue, it can eventually be applied to individuals with completely intact limbs who suffer from mobility limitations, such as stroke survivors or patients recovering from severe nerve injuries.
Looking even further into the future, Phantom Neuro’s technology lays the groundwork for seamless human augmentation. The exact same muscle-machine interface used to control a prosthetic hand could be integrated into industrial exoskeletons, allowing factory workers or logistics personnel to operate heavy machinery or extra robotic limbs naturally with their bodies. It could allow surgeons to operate remote surgical robots with flawless tactile intuition from across the world, or allow pilots to control complex unmanned systems using subtle, intuitive muscle flexes.
By proving that humans can merge with machines safely, minimally invasively, and with near-perfect accuracy, Dr. Connor Glass and Phantom Neuro are not just rewriting the future of rehabilitation; they are redefining the boundaries of what the human body can achieve.
Muscles and machines. Connor Glass on new approaches to prosthesis control.
<iframe width=”560″ height=”315″ src=”https://www.youtube.com/embed/igB9orhKTOc?si=HBDwwWRfL3CA3E9F” title=”YouTube video player” frameborder=”0″ allow=”accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share” referrerpolicy=”strict-origin-when-cross-origin” allowfullscreen></iframe>
This video interview from the Taste of Bionics series features Dr. Connor Glass discussing how the Phantom platform creates a minimally invasive muscle-machine interface to bypass brain surgery while providing intuitive control for prosthetics.
